SUMMARY In developing these international guidelines there were several unifying themes in the diagnosis and simple management of childhood asthma. For the purposes of the meeting, asthma was operationally defined as 'episodic wheeze and/or cough in a clinical setting where asthma is likely and other rarer conditions have been excluded'.
SUMMARY In developing these international guidelines there were several unifying themes in the diagnosis and simple management of childhood asthma. For the purposes of the meeting, asthma was operationally defined as 'episodic wheeze and/or cough in a clinical setting where asthma is likely and other rarer conditions have been excluded '. In making a diagnosis of asthma, a full history is a prerequisite. Additional tests are only used to support clinical impression and to provide objective evidence for therapeutic recommendations. General features of a multidisciplinary approach include an appreciation of the importance of psychosocial factors, counselling, and education. Drugs should be prescribed in a rational sequence: ,62-stimulants for mild episodic wheeze; sodium cromoglycate for mild to moderate asthma; inhaled steroids for moderate to severe asthma; with xanthines, ipratropium bromide, and oral steroids having their place in more persistent and severe cases.
Children and their parents should be reassured that if asthma is properly controlled there is no reason why the child should not lead a normal and physically active life. The management of asthma is rewarding and return to 'normal' lifestyle is nearly always possible with active participation in sporting activities.
Asthma affects more than 10% of children with a suggestion that prevalence, severity, and mortality has increased in recent years. At the same time there has been a considerable increase in prescribed treatment and hospital admissions for the disease. This is unnecessary as most patients are easily diagnosed and treated. Yet asthma remains commonly underdiagnosed and under treated.
Increased understanding of the pathology of the condition has allowed -us to make more rational decisions about therapeutic schedules. Delivery systems for inhaled preparations have improved considerably to facilitate administration even to small children. This paper represents an international agreed policy which should be of value to paediatricians and general practitioners in providing a sound basis for the diagnosis and management of childhood asthma. It is divided into sections to account for the differences between children of different ages. The protocols are outlined in the text and in simple algorithms. To facilitate a pragmatic approach to the condition, asthma is defined as 'episodic wheeze and/or cough in a clinical setting where asthma is likely and other rarer conditions have been excluded'.
Diagnosis of asthma in children unable to perform lung function tests (fig 1) The use of the label 'asthma' in older children has important clinical consequences. It implies a syndrome consisting of chronic or recurrent wheezing and/or coughing with recognisable variable airway obstruction responsive to a limited range of effective treatments. In children under 5 years, however, we can be neither so confident that wheezing is equivalent to asthma, nor that there is a homogeneous underlying pathogenesis, even in those children who do not have an alternative diagnosis. Even when we confidently make a diagnosis of asthma, the response to treatment is often unsatisfactory in the youngest age group. A number of these controversial points need to be addressed in considering a scheme for the diagnosis of asthma in this age group.
A variety of synonyms have been used to describe asthma in young children ( Wheeze is a feature of intrathoracic airway obstruction. For instance, bronchial stenosis, tracheobronchomalacia, and cystic fibrosis can cause recurrent or persistent wheeze indistinguishable from non-structural, non-focal airways obstruction (that is, asthma). Although wheeze is not synonymous with asthma, asthma is common and alternative diagnoses are rare.
As wheezing in infancy is common, it is quite clear that on occasions children with other diseases (for instance cystic fibrosis or congenital heart disease) will also suffer from asthma. From An essential aim for the management of asthma should be to train the child and/or the parents to become an effective first line in the management of symptoms and attacks so that they can cope with most of them without immediate recourse to a doctor, but also to have clear guidelines on when it is necessary to seek medical help. For small children the parents will make all the first line management decisions, but this responsibility will pass more and more to the child as adolescence approaches. They should have ready access to medical advice if long term control is poor and for acute severe attacks. Achieving this management aim necessitates instruction of the patient and parents in the use of drugs and apparatus required for asthma control. The management of asthma should be an example of 'shared caring' in which the child, the parent, and the medical advisors act as a team in managing the asthma. Information, including instructions about medication, is most conveniently given in written form so that it can be referred to from time to time. Benefit is derived from self management programmes or education packages in which children are given the same information as parents, but at an appropriate level. Such a package enables the child to recognise signals and so make decisions about self referral (to parents or doctor), self medication, and the avoidance of precipitating factors. Videos are particularly useful in teaching children. As schools are integrally involved in the daily life of the child, the family doctor should provide teachers with a record card which specifies treatment (regular drugs, prophylactics before games periods, and symptomatic relief for troublesome symptoms). Additionally children should carry with them a card which provides an action plan for emergency treatment at home and in the hospital.
PHARMACOTHERAPY
The management section is divided into four age ranges. However, there are a number of common principles which span these groups. In each case there is a progression through a number of therapeutic regimes from the treatment of mild episodic asthma through to that of chronic, persistent and severe asthma. Slow release xanthines are given in doses sufficient to produce therapeutic blood concentrations (usually equivalent to 16-24 mg/kglday of theophylline in two or three doses). When this treatment is prescribed it is important to be aware of possible side effects such as gastrointestinal symptoms, sleep disturbance, poor coordination, and impaired behaviour and learning. Oral ,82-stimulants in a twice daily, slow release formulation may be a suitable alternative.
Continuous treatment with oral steroids should be reserved for the very few cases who cannot be sufficiently controlled by other therapies. The lowest effective dose should be determined and used, and the possibility of alternate day treatment should be explored. However, this regime can normally be replaced by inhaled steroids.
Management in the 5-18 year age group (fig 6) Children over 5 years of age can use conventional inhaler devices if initial instruction is thorough. The introduction of dry powder inhalers and spacer devices has improved the success rate particularly in the early school age group (5-14 years).
02-stimulants form the first line of treatment for asthmatics in this age group. When used appropriately they can often ensure that the asthmatic child is able to lead an entirely normal life with only minimal symptoms. 02-stimulants should be administered by inhalation so that the drug is delivered to the bronchial tree for more rapid action. By this route, smaller doses can be used, and adverse effects are minimised. The drugs can be inhaled either from a metered dose inhaler or from an oxygen or compressed air driven nebuliser. The efficiency of metered dose inhalers requires 'hand-lung' coordination, which can be improved by attaching a valved spacer device to the inhaler. Alternatively, a dry powder breath activated system can be used. Oral ,62-stimulants should rarely be used in this age group, although slow release preparations are occasionally considered for nocturnal symptoms.
Sodium cromoglycate should be used when symptoms occur more frequently. In young children, sodium cromoglycate may be given by inhalation as ai dry powder. The usual starting dose is 20 mg, four times daily. When clinical response occurs, a maintenance dose of 20 mg, two or three times daily, may be adequate. A metered dose inhaler, delivering 1 mg per inhalation also has been shown to reduce asthmatic symptoms when given 2 mg, four times daily. In many countries a 5 mg metered dose inhaler is available and may be more effective in a dose of 10 mg three to four times a day. Long term use of sodium cromoglycate appears to be safe and virtually free from side effects. If troublesome coughing or wheezing are apparent, an inhaled 12-stimulant should be added as required.
Inhaled steroids in the usually recommended doses are the next step of treatment in patients with frequent episodic asthma. Higher dose inhaled steroids can be used to improve overall control of asthma but at an increased risk of side effects, including adrenal and growth suppression.
For severe and persistent symptoms xanthines can be used, although they should be instituted in a stepwise regimen with regular monitoring of blood concentrations. In some countries xanthines would be utilised at an earlier stage. Physicians should also be aware of interactions between xanthines and other drugs. Ipratropium bromide may be added when maximum response with ,62-stimulants can not be achieved without side effects. In non-responders, oral steroids are necessary.
In the adolescent age group (14-18 years) there are several special problems: (1) some teenagers smoke but may not admit this to the family or doctor. The importance of smoking as a trigger factor should be highlighted and the habit aggressively discouraged. (2) Finally an acute attack must always be considered a failure of prophylaxis and before discharge the regular treatment should be re-examined.
Direction for future clinical research into management During the course of the meeting, a number of areas were highlighted where there was clear need for further clinical research. Long term follow up studies of outcome in various situations are required. The frequency with which asthma is eventually manifested in individuals who are initially detected with asymptomatic bronchial hyperreactivity is not known. Although there is an increasing demand for early introduction of aggressive asthma prophylaxis, the long term outcome of this approach, compared with symptomatic treatment, is unknown. Many individuals who have asthma throughout childhood become asymptomatic in adolescence or early adult life, but retain persistent defects of lung function with measurable lung overinflation. It is not known whether such patients should have continuing aggressive treatment and whether this affects the possibility of recurrence of the disease in later life. Similarly, it is uncertain whether an aggressive approach to the reduction of bronchial hyper-reactivity will improve the long term prognosis. During the discussion on therapy of asthma in the less than 1 year age group, it became apparent that there were very few controlled trials of any form of treatment. In particular, identification of the most appropriate and effective delivery systems for medication is required. The group accepted that immunotherapy had been established to be superior to placebo, but comparisons of this treatment with pharmacotherapy are necessary to evalute its role in the treatment of asthma. The efficacy of environmental manipulations, including the use of filters and ionisers, also requires further investigation. It was agreed that there is a need for new modalities of treatment in very severe oral steroid dependent asthmatics, and trials of the use of methotrexate, azothioprine, cyclosporin, oral gold and troleandomycin are awaited with interest.
